CClinicalTrials.gg
Not yet recruitingNCT07700004Updated Jul 13, 2026

The King's Brief Lnterstitial Lung Disease Questionnaire

An observational study in Interstitial Lung Disease Due to Systemic Disease, sponsored by Pamukkale University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Pamukkale University · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
45
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to examine the validity and reliability of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals with Interstitial Lung Involvement Secondary to Rheumatological Diseases.

02

Conditions studied

  • Interstitial Lung Disease Due to Systemic Disease
03

In context

Lead sponsor

Pamukkale University is the lead sponsor of 331 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patient-reported outcome measurements will be administered once, and King's Brief Interstitial Lung Disease Questionnaire will be administered twice, one week apart.

Eligibility criteria

Inclusion Criteria:-Having been diagnosed with interstitial lung disease by a rheumatologist,

  • Being 18 years of age or older,
  • Agreeing to participate in the study.

Exclusion Criteria:- Presence of a neurological disease

  • Presence of any orthopedic problem that affects functionality
  • History of any orthopedic surgery in the last year
  • Inability to speak or understand Turkish fluently
  • Presence of a psychiatric illness that affects cooperation
  • Heart failure that affects daily living activities
  • Being a cancer patient
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
45 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Group I

    Interstitial Lung Involvement Secondary to Rheumatological Diseases

    Behavioral: patient reported outcome measures

Interventions

  • Behavioralpatient reported outcome measures

    King's Brief lnterstitial Lung Disease Questionnaire, Arthritis Impact Measurement Scales (AIMS2)-Short Form, Modified Medical Research Council (mMRC) Dyspnea Scale, Visual Analog Scale were evaluated.

06

What researchers measure

Primary outcomes

  1. King's Brief lnterstitial Lung Disease Questionnaire

    It consists of 15 items and has a seven-point Likert scale.

    Time frame: 10 minutes

Secondary outcomes

  1. Arthritis Impact Measurement Scales (AIMS2)-Short Form

    AIMS2-SF is a 26-item shortened form of AIMS2 and covers five components of quality of life.

    Time frame: 15 minutes

  2. Modified Medical Research Council (mMRC) Dyspnea Scale

    This scale provides information about perceived levels of shortness of breath, consisting of five stages.

    Time frame: 5 minutes

  3. Visual Analog Scale

    In our study, "respiratory distress" will be assessed using the Visual Analog Scale. 0 will be defined as "I never experience respiratory distress," and 10 as "I do not always experience respiratory distress."

    Time frame: 3 minutes

07

Study locations

1 site
  • Usak University
    Uşak, Center 64200, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07700004
Lead sponsor
Pamukkale University
Responsible party
Elif Gur Kabul (Principal investigator, Pamukkale University) — Principal investigator
First posted
Jul 13, 2026
Start date
Jul 5, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
May 15, 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

Elif Gur Kabul
Contact
elifgur1988@hotmail.com
+902762212144

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion